These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 30381260)

  • 41. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Models of α-synuclein aggregation in Parkinson's disease.
    Giráldez-Pérez R; Antolín-Vallespín M; Muñoz M; Sánchez-Capelo A
    Acta Neuropathol Commun; 2014 Dec; 2():176. PubMed ID: 25497491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The C-terminal α-helices of mammalian Hsc70 play a critical role in the stabilization of α-synuclein binding and inhibition of aggregation.
    Chaari A; Eliezer D; Ladjimi M
    Int J Biol Macromol; 2016 Feb; 83():433-41. PubMed ID: 26601760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson's Disease Associated Mutations.
    Sahay S; Ghosh D; Singh PK; Maji SK
    Curr Protein Pept Sci; 2017; 18(7):656-676. PubMed ID: 26972727
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease.
    Grassi D; Howard S; Zhou M; Diaz-Perez N; Urban NT; Guerrero-Given D; Kamasawa N; Volpicelli-Daley LA; LoGrasso P; Lasmézas CI
    Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2634-E2643. PubMed ID: 29487216
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
    Mazzulli JR; Mishizen AJ; Giasson BI; Lynch DR; Thomas SA; Nakashima A; Nagatsu T; Ota A; Ischiropoulos H
    J Neurosci; 2006 Sep; 26(39):10068-78. PubMed ID: 17005870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys.
    Chen M; Wang T; Yue F; Li X; Wang P; Li Y; Chan P; Yu S
    Neuroscience; 2015 Feb; 286():383-92. PubMed ID: 25498223
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
    El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
    FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein.
    Zagorski K; Chailyan G; Hovakimyan A; Antonyan T; Kiani Shabestari S; Petrushina I; Davtyan H; Cribbs DH; Blurton-Jones M; Masliah E; Agadjanyan MG; Ghochikyan A
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682759
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease.
    Barrenschee M; Zorenkov D; Böttner M; Lange C; Cossais F; Scharf AB; Deuschl G; Schneider SA; Ellrichmann M; Fritscher-Ravens A; Wedel T
    Acta Neuropathol Commun; 2017 Jan; 5(1):1. PubMed ID: 28057070
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts.
    Ardah MT; Ghanem SS; Abdulla SA; Lv G; Emara MM; Paleologou KE; Vaikath NN; Lu JH; Li M; Vekrellis K; Eliezer D; El-Agnaf OMA
    BMC Complement Med Ther; 2020 Mar; 20(1):73. PubMed ID: 32143619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines.
    Perrin RJ; Payton JE; Barnett DH; Wraight CL; Woods WS; Ye L; George JM
    Neurosci Lett; 2003 Oct; 349(2):133-5. PubMed ID: 12946570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease.
    Macchi F; Deleersnijder A; Van den Haute C; Munck S; Pottel H; Michiels A; Debyser Z; Gerard M; Baekelandt V
    J Neurosci Methods; 2016 Mar; 261():117-27. PubMed ID: 26620202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
    Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
    Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation Approach.
    Rousseaux MWC; Vázquez-Vélez GE; Al-Ramahi I; Jeong HH; Bajić A; Revelli JP; Ye H; Phan ET; Deger JM; Perez AM; Kim JY; Lavery LA; Xu Q; Li MZ; Kang H; Kim JJ; Shulman JM; Westbrook TF; Elledge SJ; Liu Z; Botas J; Zoghbi HY
    J Neurosci; 2018 Oct; 38(43):9286-9301. PubMed ID: 30249792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel DNA Aptamers for Parkinson's Disease Treatment Inhibit α-Synuclein Aggregation and Facilitate its Degradation.
    Zheng Y; Qu J; Xue F; Zheng Y; Yang B; Chang Y; Yang H; Zhang J
    Mol Ther Nucleic Acids; 2018 Jun; 11():228-242. PubMed ID: 29858057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Female Sex and Brain-Selective Estrogen Benefit α-Synuclein Tetramerization and the PD-like Motor Syndrome in 3K Transgenic Mice.
    Rajsombath MM; Nam AY; Ericsson M; Nuber S
    J Neurosci; 2019 Sep; 39(38):7628-7640. PubMed ID: 31405930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.